9C2H
 
 | | SARS-CoV-2 Nucleocapsid Dimerization Domain bound to Fab-NP1E9 and Fab-NP3B4 | | Descriptor: | Antibody Fab NP1-E9 Heavy Chain (variable region), Antibody Fab NP1-E9 Light Chain (variable region), Antibody Fab NP3-B4 Heavy Chain (variable region), ... | | Authors: | Landeras-Bueno, S, Hariharan, C, Diaz Avalos, R, Ollmann Saphire, E. | | Deposit date: | 2024-05-31 | | Release date: | 2025-05-14 | | Method: | ELECTRON MICROSCOPY (3.7 Å) | | Cite: | Structural stabilization of the intrinsically disordered SARS-CoV-2 N by binding to RNA sequences engineered from the viral genome
To Be Published
|
|
9F7P
 | |
9F7R
 | |
9F7S
 | |
9F7U
 | |
9LVR
 | | Crystal structure of SARS-CoV-2 3CL protease in complex with compound 1 | | Descriptor: | 1,2-ETHANEDIOL, 3C-like proteinase nsp5, 6-(1,3-dihydroisoindol-2-yl)-3-(5-methylpyridin-3-yl)-1-[[3,4,5-tris(fluoranyl)phenyl]methyl]-1,3,5-triazine-2,4-dione | | Authors: | Unoh, Y, Hirai, K, Uehara, S, Kawashima, S, Nobori, H, Sato, J, Shibayama, H, Hori, A, Nakahara, K, Kurahashi, K, Takamatsu, M, Yamamoto, S, Zhang, O, Tanimura, M, Dodo, R, Maruyama, Y, Sawa, H, Watari, R, Miyano, T, Kato, T, Sato, T, Tachibana, Y. | | Deposit date: | 2025-02-12 | | Release date: | 2025-05-14 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19
To Be Published
|
|
9FCM
 | | Single-domain antibody binding the SARS-COV2 S2 | | Descriptor: | CHLORIDE ION, Single-domain antibody R3DC23, Spike protein S2' | | Authors: | Vann Molle, I, Remaut, H. | | Deposit date: | 2024-05-15 | | Release date: | 2025-05-21 | | Last modified: | 2025-06-11 | | Method: | X-RAY DIFFRACTION (1.94 Å) | | Cite: | Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base.
Nat Commun, 16, 2025
|
|
9UJ2
 | | 14-3-3 zeta chimera with the S202R peptide of SARS-CoV-2 N (residues 200-213) | | Descriptor: | 1,2-ETHANEDIOL, 14-3-3 protein zeta/delta,Peptide from Nucleoprotein, DI(HYDROXYETHYL)ETHER | | Authors: | Boyko, K.M, Matyuta, I.O, Minyaev, M.E, Perfilova, K.V, Sluchanko, N.N. | | Deposit date: | 2025-04-16 | | Release date: | 2025-05-21 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | High-resolution structure reveals enhanced 14-3-3 binding by a mutant SARS-CoV-2 nucleoprotein variant with improved replicative fitness.
Biochem.Biophys.Res.Commun., 767, 2025
|
|
9ELE
 | |
9ELF
 | |
9ELG
 | |
9ELH
 | |
9ELI
 | |
9ELO
 | |
9ELQ
 | |
9HH5
 | | Crystal Structure of nsp15 Endoribonuclease from SARS CoV-2 in Complex with Sepantronium (YM-155) | | Descriptor: | 1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, Nsp15 - Uridylate-specific endoribonuclease, ... | | Authors: | Chatziefthymiou, S.D, Kolbe, M, Hakanpaeae, J, Labahn, J, Windshuegel, B. | | Deposit date: | 2024-11-21 | | Release date: | 2025-05-28 | | Method: | X-RAY DIFFRACTION (2.08 Å) | | Cite: | Identification, validation, and characterization of approved and investigational drugs interfering with the SARS-CoV-2 endoribonuclease Nsp15.
Protein Sci., 34, 2025
|
|
9HH6
 | | Crystal Structure of Nsp15 Endoribonuclease from SARS CoV-2 in Complex with TAS-103 | | Descriptor: | 1,2-ETHANEDIOL, 6-[2-(dimethylamino)ethylamino]-3-oxidanyl-indeno[2,1-c]quinolin-7-one, ORF1ab polyprotein, ... | | Authors: | Chatziefthymiou, S.D, Kolbe, M, Hakanpaeae, J, Labahn, J, Windshuegel, B. | | Deposit date: | 2024-11-21 | | Release date: | 2025-05-28 | | Method: | SOLUTION SCATTERING (2 Å), X-RAY DIFFRACTION | | Cite: | Identification, validation, and characterization of approved and investigational drugs interfering with the SARS-CoV-2 endoribonuclease Nsp15.
Protein Sci., 34, 2025
|
|
9IZB
 | |
9ELK
 | |
9ELL
 | |
9ELM
 | |
9ML4
 | |
9ML5
 | |
9ML6
 | |
9ML7
 | |
